FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves a supplemental application for KYPROLIS (carfilzomib) from Onyx Pharmaceuticals. This action finalizes an update to KYPROLIS's regulatory status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Kyprolis (carfilzomib)

Snippet

SUPPL AP for KYPROLIS (CARFILZOMIB)